Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
According to the World Health Organisation's latest update, # 39, as of the 26th of May the latest figures in the influenza A H1N1 (swine flu) outbreak are 12,954 confirmed cases in 46 countries, including 92 deaths.
Concerns regarding the H1N1 flu strain or the current global economic recession should not take attention away from the long-term fight against HIV/AIDS, Julio Mantaner, head of the International AIDS Society, said recently, VOA News reports.
Researchers at the University of Maryland School of Medicine have found that an approved drug for treating rheumatoid arthritis reduces severe illness and death in mice exposed to the Influenza A virus. Their findings suggest that tempering the response of the body's immune system to influenza infection may alleviate some of the more severe symptoms and even reduce mortality from this virus.
Sanofi Pasteur announced today it has received the first of what is expected to be a series of orders from the U.S. Department of Health and Human Services (HHS) to commence production of a vaccine to help protect against the new influenza A(H1N1) virus.
The latest update, # 37, from the World Health Organisation on the influenza A H1N1 (swine flu) outbreak says as of the 23rd of May, 43 countries have now officially reported 12,022 cases, including 86 deaths.
HHS Secretary Kathleen Sebelius has announced that the department will take important steps necessary to prepare for potential commercial-scale production of a candidate vaccine for the novel Influenza A ( H1N1).
In just two weeks from the time the first patient virus samples were made available, Singapore scientists report an evolutionary analysis of a critical protein produced by the 2009 H1N1 influenza A virus strain.
Australia's 10th confirmed case of influenza A H1N1 (swine flu) has appeared in Adelaide in South Australia - the first case for that state.
The 62nd World Health Assembly, which brought together health ministers and senior health officials from WHO's Member States, closed today with the adoption of resolutions on a variety of global health issues including primary health care, the prevention and control of multidrug- resistant and extensively drug-resistant tuberculosis, public health, innovation and intellectual property and pandemic influenza preparedness. The Health Assembly also passed the Programme Budget for 2010 -2011.
To fulfill America's humanitarian obligations as a member of the international community and to invest in the nation's long-term health, economic interests, and national security, the United States should reaffirm and increase its commitment to improving the health of developing nations, says a new report from the Institute of Medicine.
The ability to mount an immune response to influenza A (H1N1) infection is significantly compromised by a low level of arsenic exposure that commonly occurs through drinking contaminated well water, scientists at the Marine Biological Laboratory (MBL) and Dartmouth Medical School have found.
Australia's recorded cases of the new H1N1 flu (Swine flu) has now reached 3 with the confirmation of two new cases.
Current epidemiological information suggests that the influenza A (H1N1) virus transmissibility potential is at least comparable to that of seasonal influenza viruses, with ability to sustain community spread. There is therefore no reason to expect that ongoing spread of the virus will stop.
The latest figures from the World Health Organisation (WHO) has the worldwide influenza A H1N1 (swine flu) tally fast approaching 10,000 human cases.
What happens if the next big influenza mutation proves resistant to the available anti-viral drugs? This question is presenting itself right now to scientists and health officials this week at the World Health Assembly in Geneva, Switzerland, as they continue to do battle with H1N1, the so-called swine flu, and prepare for the next iteration of the ever-changing flu virus.
With the current outbreak of swine flu, and in the absence of a vaccine or treatment at present, the only way to contain the virus is to get people around the world to take precautionary measures.
WHO Director-General Dr Margaret Chan and United Nations Secretary-General Ban Ki-moon met with over 30 vaccine manufacturers from developing and developed countries at WHO headquarters today.
Researchers have successfully tested first the first time a computer simulation of major portions of the body's immune reaction to influenza type A, with implications for treatment design and preparation ahead of future pandemics, according to work accepted for publication, and posted online, by the Journal of Virology.
The 62nd World Health Assembly opened today in Geneva, as officials from 193 member countries began their annual review of the activities of the WHO and set new priorities for the future.
The latest update from the World Health Organization (WHO) # 31, says as of 17th May that 39 countries have now officially reported a total of 8,480 cases of influenza A(H1N1) infection.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.